Archives

Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for ADLARITY^® (donepezil transdermal system) for the Treatment of Alzheimer’s Disease
MENLO PARK, Calif., January 27, 2020 (GLOBE NEWSWIRE) – Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for patients and their families, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for ADLARITY (donepezil transdermal system), its lead investigational agent for the treatment of dementia of the Alzheimer’s type in patients with mild, moderate, and severe Alzheimer’s disease. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of July 30^th, 2020.

Corium Appoints Perry Sternberg as Chief Executive Officer
MENLO PARK, Calif., April 2, 2019 (GLOBE NEWSWIRE) – Corium, Inc. announced today that its Board of Directors has named Perry Sternberg as Chief Executive Officer. Mr. Sternberg is a senior pharmaceutical executive with commercial experience across a wide range of therapeutic areas in diverse markets…

Gurnet Point Capital Announces Completion of Tender Offer
CAMBRIDGE, Mass., November 27, 2018 – Gurnet Point Capital (“Gurnet Point”), a private investment firm focused on the healthcare and life sciences sectors, announced today that it has completed the previously announced tender offer for all outstanding shares of common stock of Corium International, Inc. (Nasdaq: CORI) (“Corium”), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products….

Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares
Total Transaction Valued in Excess of $500 Million , Representing a 50% Premium Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium’s Corplex Donepezil MENLO PARK, Calif. , Oct. 11, 2018 (GLOBE NEWSWIRE) — Corium International, Inc….

Corium to Present at the 2018 Cantor Fitzgerald Global Heathcare Conference
MENLO PARK, Calif. , Sept. 24, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple , Corium’s President and…